CEO Jakob Lindberg on Oncopeptides and Ygalo.
Oncopeptides is a clinical development pharmaceutical company focused on bringing anti-cancer research as treatments for the benefit of patients.
Oncopeptides is currently in late-stage development and is undertaking registration studies for Ygalo®, the first targeted cytotoxic therapy intended for use in the treatment of multiple myeloma. The first indication is late-stage relapsed and refractory multiple myeloma.
Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug. Ygalo differs from current cytotoxics through its unique ability to achieve higher concentrations of cancer killing molecules in cancer cells without a corresponding increase in damage to the patient’s bone marrow. Pre-clinical studies also show that Ygalo kills on average 50 times more cancer cells than similar classes of treatment.
Ygalo is an alkylating agent that leverages the overrepresentation of peptidase enzymes in cancer cells to increase the concentration of active cancer fighting molecules in myeloma cells: it is a peptidase potentiated alkylator.